Market capitalization | $19.78m |
Enterprise Value | $-9.30m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | -1.42 |
P/S ratio (TTM) P/S ratio | 3.02 |
P/B ratio (TTM) P/B ratio | 0.57 |
Revenue growth (TTM) Revenue growth | 282.90% |
Revenue (TTM) Revenue | $6.56m |
EBIT (operating result TTM) EBIT | $-16.86m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
1 Analyst has issued a forecast Sol-Gel Technologies Ltd.:
1 Analyst has issued a forecast Sol-Gel Technologies Ltd.:
Jun '24 |
+/-
%
|
||
Revenue | 6.56 6.56 |
284%
284%
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -17 -17 |
37%
37%
|
Net Profit | -15 -15 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.
Head office | Israel |
CEO | Alon Seri-Levy |
Employees | 36 |
Founded | 1997 |
Website | www.sol-gel.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.